Comparison of bezafibrate versus lovastatin for lowering plasma insulin fibrinogen and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients

American Journal of Cardiology

Volumn 80, Issue 7, 1997, Pages 836-840

  Zambrana, José L ^a   Velasco, Francisco ^a   Castro, Pedro ^a   Concha, Manuel ^a   Vallés, Federico ^a   Montilla, Pedro ^a   Jimenéz Perepérez, Jose A ^a   López Miranda, Jose ^a   Pérez Jiménez, Francisco ^a  

^a U Transplante Cardiaco Hosp U   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BEZAFIBRATE; CYCLOSPORIN; DEFLAZACORT; FIBRINOGEN; INSULIN; MEVINOLIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; FIBRINOGEN BLOOD LEVEL; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN BLOOD LEVEL; LIPID METABOLISM; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTILIPEMIC AGENTS; BEZAFIBRATE; CROSS-OVER STUDIES; FEMALE; FIBRINOGEN; HEART TRANSPLANTATION; HUMANS; HYPERLIPIDEMIAS; INSULIN; LOVASTATIN; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES;

EID: 0030726787     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00532-8     Document Type: Article

References (28)

1. Peters JR, Kubo SH, Olivari MT, Knutson KR, Hunninghake DB. Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil ± lovastatin. Am J Cardiol. 71:1993;1485-1488.
2. Hidalgo L, Zambrana JL, Blanco A, Lopez-Granados A, Concha M, Cesares J, Jimenez-Pereperez JA, Lopez-Miranda J, Perez-Jimenez F. Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation. J Heart Lung Transplant. 14:1995;461-467.
3. Monk JP, Todd PA. Bezafibrate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidemia. Drugs. 33:1987;539-576.
4. Leschke M, Podder M, Jehle J, Strauer E. Influence of long-term bezafibrate therapy on lipid parameters, fibrinogen and plasma viscosity. Ernst E, Koening W, Lowe GDO, Meade TW. Fibrinogen: A "New" Cardiovascular Risk Factor. 1993;380-383 Blackwell MTV, Vienna.
5. Jones IR, Swai A, Taylor R, Miller M, Laker MF, Alberti KG. Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care. 13:1990;855-863.
6. Lovastatin five year safety and efficacy study. Arch Intern Med. 153:1993;1079-1087.
7. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med. 148:1988;36-69.
8. Prevention of Coronary Heart Disease: Scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease. Nutr Metab Cardiovasc Dis. 2:1992;113-156.
9. Zambrana JL, López-Miranda J, Anguita M, Blanco J, Vallés F, Casares J, Muñoz Carvajal I, Jiménez-Perepérez JA, Pérez Jiménez I. Comparación del tratamiento con bezafibrato y lovastatina a dosis habituales en la hiperlipidemia postrasplante cardiaco. Rev Esp Cardiol. 49:1996;892-898.
10. Hunt BJ, Segal H, Yacoub M. Hemostatic changes in heart transplant recipients and their relationship to accelerated coronary sclerosis. Transplantation. 55:1993;309-315.
11. Hunt BJ, Segal H, Yacoub M. Fibrinogen levels in heart transplant recipients (HTRs) and their relationship to transplant-associated atheroma. Ernst E, Koening W, Lowe GDO, Meade TW. Fibrinogen: A "New" Cardiovascular Risk Factor. 1993;218-222 Blackwell MTV, Vienna.
12. Kemna MS, Valantine HA, Hunt SA, Schroeder JS, Chen YD, Reaven GM. Metabolic risk factors for atherosclerosis in heart transplant recipients. Am Heart J. 128:1994;68-72.
13. Grady KL, Costanzo-Nordin MR, Herold LS, Sriniavasan S, Pifarre R. Obesity and hyperlipidemia after heart transplantation. J. Heart Lung Transplant. 10:1991;449-454.
14. Karhapaa P, Uusitupa M, Voutilainen E, Laakso M. Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia. Clin Pharmacol Ther. 52:1992;620-626.
15. Avogaro A, Beltramello P, Marin R, Zambon S, Bonanome A, Biffanti S, Confortin L, Manzato E, Crepaldi G, Tiengo A. Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients. Atherosclerosis. 113:1995;117-124.
16. McCrea JB, Fruncillo RJ, Holland SD, Conroy JA, Shingo S, Spector R, Bjornsson TD. Lovastatin does not affect oral glucose tolerance in hypercholesterolemic patients. J Clin Pharmacol. 33:1993;581-585.
17. Golay A, Swislocki ALM, Chen T-DI, Reaven GM. Relationships between plasma free fatty acid concentration, endogenous glucose production and fasting hyperglycemia in normal and non-insulin dependent diabetic individuals. Metabolism. 36:1987;692-696.
18. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest. 72:1983;1737-1747.
19. Kobayashi J, Takahashi K, Tashiro J, Shirai K, Saito Y, Yoshida S, Hashimoto H, Fukamachi I, Niihara K, Sasaki N. Effects of treatment with bezafibrate on lipoprotein lipase activity and mass in patients with hypertriglyceridemia. Arzneimittelforschung. 44:1994;145-148.
20. Barbir M, Hunt B, Kushwaha S, Kehely A, Prescot R, Thompson GR, Mitchell A, Yacoub M. Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients. Am J Cardiol. 70:1992;1596-1601.
21. Winocour PH, Durrington PN, Bhatnagar D, Ishola M, Arrol S, Lalor BC, Anderson DC. Double blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins and fibrinogen in hyperlipidemic type 1 diabetes mellitus. Diabetes Med. 7:1990;736-743.
22. Andersen P, Smith P, Seljeflot I, Brataker S, Arnesen H. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemost. 63:1990;174-177.
23. Fujii S, Sawa H, Sobel BE. Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil. Thromb Haemost. 70:1993;642-647.
24. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 34:1991;457-462.
25. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. Circulation. 89:1994;321-330.
26. López-Segura F, Velasco F, Lopez-Miranda J, Castro P, López-Pedrera R, Blanco A, Jiménez-Perepérez JA, Torres A, Trujillo J, Ordovaś JM, Pérez-Jiménez F. Monounsaturated fatty acid-enriched diet decreases plasma plasminogen activator inhibitor type 1. Arterioscl Thromb Vasc Biol. 16:1996;82-88.
27. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 313:1985;1557-1563.
28. Isaacsohn JL, Setaro JF, Nicholas C, Davey JA, Diotalevi LJ, Christianson DS, Liskov E, Stein EA, Black HR. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am J Cardiol. 74:1994;735-737.